Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Shi, Jufang; Wang, Le; Wu, Ning; Li, Junling; Hui, Zhouguang; Liu, Shangmei; Yang, Boyan; Gao, Shugeng; Ren, Jiansong; Huang, Huiyao; Zhu, Juan; Liu, Chengcheng; Fan, Jin‐Hu; Zhao, Suping; Xing, Puyuan; Zhang, Ye; Li, Ning; Lei, Wendong; Wang, Debin; Huang, Yunchao; Liao, Xianzhen; Xing, Xiaojing; Du, Lingbin; Li, Yang; Liu, Yuqin; Zhāng, Yǒng-Zhèn; Zhang, Kai; Qiao, You‐Lin; He, Jie; Dai, Min

doi:10.1016/j.lungcan.2018.11.031

Cited by 82 publications

(59 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lung cancer detected by low-dose computerized tomography is most likely to be peripherally located ADC, which is an alternative explanation for the increasing incidence of ADC (28). However, China has promoted the use of low-dose computerized tomography as a national public health strategy for screening high-risk groups for lung cancer since 2012, which also may have limited impact on the current results (29).…”

Section: Discussionmentioning

confidence: 99%

Secular trends in incidence of lung cancer by histological type in Beijing, China, 2000−2016

Yang

Wang

Yuan

et al. 2019

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective The objective of this study was to characterize secular trends in the sex-specific, age-standardized incidence of lung cancer by histological type in Beijing, China, from 2000 to 2016 based on data from a population-based cancer registry. Methods Data on the incidence of cancer from 2000 to 2016 were obtained from the Beijing Cancer Registry. We examined trends in the sex-specific, age-standardized incidence of lung cancer by histological type using a Joinpoint regression model. Results A total of 117,409 cases of lung cancer were diagnosed from 2000 to 2016. Overall, 73,062 (62.23%) patients were males. The most common histological type among both sexes was adenocarcinoma; however, the proportion of adenocarcinoma differed significantly between males and females (45.36% vs . 77.14%, respectively, P<0.0001). The age-standardized incidence of total lung cancer increased from 2000 to 2010 with an annual percent change (APC) of 2.2% [95% confidence interval (95% CI), 1.5% to 2.9%] and stabilized thereafter. Among males, the incidence of total lung cancer peaked in 2008 and then decreased slightly, with an APC of −1.1% (95% CI, −2.1% to −0.1%). Among females, the incidence increased continuously during the study period, with an APC of 1.4% (95% CI, 0.9% to 1.9%). The incidence of squamous cell carcinoma decreased significantly in recent years among both sexes, with APCs of −2.6% (95% CI, −4.5% to −0.6%) from 2007 to 2016 for males and −5.4% (95% CI, −7.2% to −3.6%) from 2004 to 2016 for females. In contrast, the incidence of adenocarcinoma increased continuously throughout the study period, by APCs of 4.0% (95% CI, 2.6% to 5.4%) for males and 6.2% (95% CI, 4.8% to 7.6%) for females. The incidence of small cell carcinoma peaked in 2007 and stabilized thereafter among males, whereas it peaked in 2012 and then decreased with an APC of −14.7% (95% CI, −25.3% to −2.6%) among females. The incidence of large cell carcinoma and other specified malignant neoplasm did not change much, whereas the incidence of unspecified type decreased among both sexes during the study period. Conclusions Although the incidence of squamous cell carcinoma decreased significantly among both sexes in recent years in Beijing, China, adenocarcinoma increased continuously throughout the study period among both sexes. Knowledge of differences in trends is useful for surveillance and control of lung cancer. However, the reason for the increase in adenocarcinoma remains unclear and warrants investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Secular trends in incidence of lung cancer by histological type in Beijing, China, 2000−2016

Yang

Wang

Yuan

et al. 2019

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…The details of the hospital selection and case sampling methods have been described previously . To ensure that our sample was geographically representative of China, we included eight tertiary hospitals from seven regions, including the North, Northeast, Central, South, East, Northwest, and Southwest, based on the traditional administrative district definitions by the National Bureau of Statistics using convenience sampling; the hospitals were the Shanxi Provincial Cancer Hospital (in Shanxi Province, North China), Liaoning Cancer Hospital (in Liaoning Province, Northeast China), Zhejiang Cancer Hospital (in Zhejiang Province, East China), Anhui Cancer Hospital (in Anhui Province, East China), Hunan Cancer Hospital (in Hunan Province, Central China), Guangxi Cancer Hospital (in Guangxi Autonomous Region, South China), Yunnan Cancer Hospital (in Yunnan Province, Southwest China), and Gansu Provincial Hospital (in Gansu Province, Northwest China) . The selected hospitals provided the medical records of patients with lung cancer diagnosed from 2005 to 2014.…”

Section: Methodsmentioning

confidence: 99%

What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Most lung cancer patients are diagnosed after the onset of symptoms. However, whether the symptoms of lung cancer were independently associated with the diagnosis of lung cancer is unknown, especially in the Chinese population. Methods We conducted a 10 years (2005‐2014) nationwide multicenter retrospective clinical epidemiology study of lung cancer patients diagnosed in China. As such, this study focused on nonsmall cell lung cancer (NSCLC). We calculated the odds ratios (ORs) for variables associated with the symptoms and physical signs using multivariate unconditional logistic regressions. Results A total of 7184 lung cancer patients were surveyed; finally, 6398 NSCLC patients with available information about their symptoms and physical signs were included in this analysis. The most common initial symptom and physical sign was chronic cough (4156, 65.0%), followed by sputum with blood (2110, 33.0%), chest pain (1146, 17.9%), shortness of breath (1090, 17.0%), neck and supraclavicular lymphadenectasis (629, 9.8%), weight loss (529, 8.3%), metastases pain (378, 5.9%), fatigue (307, 4.8%), fever (272, 4.3%), and dyspnea (270, 4.2%). Patients with squamous carcinoma and stage III disease were more likely to present with chronic cough ( P < 0.0001) and sputum with blood ( P < 0.0001) than patients with other pathological types and clinical stages, respectively. Metastases pain ( P < 0.0001) and neck and supraclavicular lymphadenectasis ( P = 0.0006) were more likely to occur in patients with nonsquamous carcinoma than in patients with other carcinomas. Additionally, patients with stage IV disease had a higher percentage of chest pain, shortness of breath, dyspnea, weight loss, and fatigue than patients with other stages of disease. In multivariable logistic analyses, compared with patients with adenocarcinoma, patients with squamous carcinoma were more likely to experience symptoms (OR = 2.885, 95% confidence interval [CI] 2.477‐3.359) but were less likely to present physical signs (OR = 0.844, 95% CI 0.721‐0.989). The odds of having both symptoms and physical signs were higher in patients with late‐stage disease than in those with early‐stage disease ( P < 0.0001). Conclusions The symptoms and physical signs of lung cancer were associated with the stage and pathological diagnosis of NSCLC. Patients with squamous carcinoma were more likely to develop symptoms, but not signs, than patients with adenocarcinoma. The more advanced the stage at diagnosis, the more likely that symptoms or physical signs are to develop. Further prospective cohort studies are needed to explore these results.

show abstract

“…Lung cancer mainly has two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung adenocarcinoma (LUAD) and squamous cell carcinoma are the two main types of NSCLC, accounting for 40% of cases [ 4 ]. Molecular targeting therapies significantly improved prognosis in patients with LUAD.…”

Section: Introductionmentioning

confidence: 99%

Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma

Zhu

Wang

2020

International Journal of Genomics

View full text Add to dashboard Cite

Background. There is plenty of evidence showing that immune-related genes (IRGs) and epigenetic modifications play important roles in the biological process of cancer. The purpose of this study is to establish novel IRG prognostic markers by integrating mRNA expression and methylation in lung adenocarcinoma (LUAD). Methods and Results. The transcriptome profiling data and the RNA-seq data of LUAD with the corresponding clinical information of 543 LUAD cases were downloaded from The Cancer Genome Atlas (TCGA) database, which were analyzed by univariate Cox proportional regression and multivariate Cox proportional regression to develop an independent prognostic signature. On the basis of this signature, we could divide LUAD patients into the high-risk, medium-risk, and low-risk groups. Further survival analyses demonstrated that high-risk patients had significantly shorter overall survival (OS) than low-risk patients. The signature, which contains 8 IRGs (S100A16, FGF2, IGKV4-1, CX3CR1, INHA, ANGPTL4, TNFRSF11A, and VIPR1), was also validated by data from the Gene Expression Omnibus (GEO) database. We also conducted analyses of methylation levels of the relevant IRGs and their CpG sites. Meanwhile, their associations with prognosis were examined and validated by the GEO database, revealing that the methylation levels of INHA, S100A16, the CpG site cg23851011, and the CpG site cg06552037 may be used as the potential regulators for the treatment of LUAD. Conclusion. Collectively, INHA, S100A16, the CpG site cg23851011, and the CpG site cg06552037 are promising biomarkers for monitoring the outcomes of LUAD.

show abstract

Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Cited by 82 publications

References 35 publications

Secular trends in incidence of lung cancer by histological type in Beijing, China, 2000−2016

Secular trends in incidence of lung cancer by histological type in Beijing, China, 2000−2016

What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China

Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma

Contact Info

Product

Resources

About